A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan (SIRINOX)
A Phase I Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan in Patients With Advanced or Metastatic Digestive Adenocarcinoma as First- or Second-line Treatment
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Listed as NCT02387138, this PHASE1 trial focuses on Digestive Cancer and remains completed. Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle, it has been updated 8 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Unknown Status → Recruiting
-
May 2017 — Sep 2017 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE1
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut du Cancer de Montpellier - Val d'Aurelle
For direct contact, visit the study record on ClinicalTrials.gov .